STOCK TITAN

Evotec Ag - EVO STOCK NEWS

Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.

Evotec AG (EVO) is a globally operating life sciences company specializing in drug discovery, development, and biologics manufacturing. Headquartered in Hamburg, Germany, the company collaborates with a wide range of stakeholders, including pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists, to accelerate the development of first-in-class and best-in-class therapeutics. Evotec's unique business model integrates cutting-edge technologies, data-driven insights, and scientific expertise to deliver innovative solutions across the pharmaceutical value chain.

Comprehensive Business Model

Evotec operates through two primary segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, which constitutes a significant portion of its revenue, provides integrated drug discovery and development services. These include early-stage research, preclinical development, and manufacturing support, often structured as fee-for-service contracts or collaborative partnerships. The company also engages in co-owned R&D projects, creating a robust pipeline of over 200 proprietary and co-owned assets spanning therapeutic areas such as neurology, oncology, metabolic diseases, and infectious diseases.

The Just-Evotec Biologics segment focuses on contract development and manufacturing organization (CDMO) services for biologics. Leveraging its proprietary J.POD® technology, this segment offers scalable, continuous manufacturing solutions that address cost, flexibility, and risk challenges in biologics production. This innovative approach enables the production of biotherapeutics in flexible quantities, making it particularly valuable for transitioning from clinical to commercial scales.

Operational Excellence and Technological Integration

Evotec's multimodality platform combines advanced technologies such as artificial intelligence (AI), machine learning (ML), and high-throughput screening to enhance drug discovery and development. The company’s sites in Europe and the United States operate as synergistic clusters of excellence, providing seamless integration of services and technologies. This strategic infrastructure supports a broad range of therapeutic modalities, including small molecules, biologics, and cell therapies.

Notable innovations include the J.POD® continuous manufacturing facilities in the U.S. and Europe, which set new benchmarks for efficiency and sustainability in biologics production. Additionally, Evotec's AI/ML-driven platforms enable data-rich drug discovery processes, significantly reducing the time and cost associated with early-stage development.

Strategic Partnerships and Global Reach

Evotec collaborates with all Top 20 pharmaceutical companies, along with over 800 biotechnology firms, academic institutions, and other healthcare stakeholders. These partnerships are pivotal in co-creating high-value pipelines and accelerating the translation of academic discoveries into clinical candidates. The company’s collaborative initiatives, such as LAB eN² with Novo Nordisk and its partnership with Boston University and Harvard, underscore its commitment to addressing unmet medical needs through innovation and collaboration.

Position in the Competitive Landscape

Operating in a highly competitive market, Evotec distinguishes itself through its co-owned pipeline model, technological capabilities, and focus on underserved therapeutic areas. Competitors like Charles River Laboratories, Lonza, and Catalent primarily offer traditional fee-for-service models, whereas Evotec’s integrated approach combines R&D expertise with proprietary technologies to deliver superior value to its partners. The company's emphasis on biologics and cell therapies further enhances its competitive edge in a rapidly evolving industry.

Key Therapeutic Areas

Evotec focuses on several high-impact therapeutic areas, including:

  • Neurology: Addressing complex central nervous system disorders with innovative drug candidates.
  • Oncology: Developing targeted therapies for various cancer types.
  • Metabolic Diseases: Advancing treatments for diabetes and related conditions.
  • Infectious Diseases: Tackling global health challenges with novel anti-infective agents.

Commitment to Innovation and Sustainability

Evotec’s commitment to innovation extends to its environmental sustainability initiatives. The J.POD® facilities, for example, are designed to minimize water, electricity, and chemical usage, reflecting the company’s focus on reducing its environmental footprint while delivering cutting-edge solutions.

With a workforce of over 5,000 highly skilled professionals and a global presence, Evotec continues to redefine the boundaries of drug discovery and development. Its unique combination of technological innovation, collaborative partnerships, and strategic focus on underserved therapeutic areas positions it as a key player in the life sciences industry.

Rhea-AI Summary

Exscientia (NASDAQ: EXAI) has announced a breakthrough in identifying patient responders to its A2A receptor antagonist, EXS-21546. Highlighting new data, the company revealed the adenosine burden score (ABS) that predicts the effectiveness of the drug in combating tumor immunosuppression. Exscientia is set to confirm ABS's validity in its upcoming IGNITE-AI Phase 1/2 trial, which combines '546 with a checkpoint inhibitor for patients with relapsed renal cell carcinoma and non-small cell lung cancer. This research will be presented at the ESMO Immuno-Oncology Congress from December 7-9 in Geneva.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
-
Rhea-AI Summary

Exscientia announced the approval of the IGNITE-AI clinical trial for EXS-21546, an A2A receptor antagonist, targeting relapsed/refractory renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). The trial aims to enroll up to 110 patients to assess safety, efficacy, and pharmacokinetics. Notably, a unique biomarker signature will guide patient selection. The trial's first phase will establish the maximum tolerated dose, followed by an expansion phase to confirm efficacy. This is a significant step for Exscientia, enhancing its precision medicine approach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
-
Rhea-AI Summary

Evotec SE, a leading life science company, reported a 19% revenue increase to €510.8 million for the first nine months of 2022, despite lower milestone payments compared to 2021. The base business grew by 27% to €502.7 million. Adjusted EBITDA decreased to €44.6 million due to high expansion costs and inflated energy prices. The company also announced multiple drug discovery agreements and launched its multi-omics data analysis platform PanHunter. The full-year revenue outlook remains unchanged, targeting between €715-735 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
Rhea-AI Summary

Evotec SE will announce its financial results for the first nine months of 2022 on November 9, 2022. A conference call will be held on the same day at 2:00 PM CET to discuss these results and provide a performance update. Participants can join via phone or through an audio webcast. Evotec operates globally with over 4,500 employees and focuses on discovering and developing therapeutics across various therapeutic areas, including neurology and oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
none
-
Rhea-AI Summary

Evotec SE announced the completion of its acquisition of Central Glass Germany GmbH from Central Glass Co. Ltd. This strategic move enhances Evotec's drug substance manufacturing capacity, particularly focusing on rare diseases and precision therapeutics. The facility, located in Halle/Westphalia, Germany, is now operational and employs around 60 experts in chemical manufacturing. Evotec plans significant investments to establish this site as a leading center for rare disease drug substance manufacturing in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
-
Rhea-AI Summary

Evotec SE presented a transformative update on biologics manufacturing at its Capital Markets Day, focusing on global access to biotherapeutics. The company’s subsidiary, Just - Evotec Biologics, showcased its integrated AI/ML-based technologies, emphasizing a paradigm shift in the industry. Significant highlights include a $49.9 million contract with the U.S. Department of Defense for monoclonal antibody prototypes and the groundbreaking of a new manufacturing facility in Toulouse, France. CEO Dr. Werner Lanthaler underscored the need for modernized manufacturing to enhance accessibility to essential therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
Rhea-AI Summary

Evotec SE has launched a new translational partnership named Extend in collaboration with CDP Venture Capital and Angelini Ventures. This initiative aims to enhance drug discovery efforts by forming partnerships with esteemed academic institutions across Italy. The Extend initiative seeks to translate innovative academic research into actionable data, facilitating the creation of spin-off companies. Key institutions involved include Ospedale San Raffaele and several universities from Milan, Florence, and Padua. This venture is part of Evotec's broader strategy to foster innovation and accelerate commercialization of promising therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
partnership
-
Rhea-AI Summary

Evotec has partnered with Hannover Medical School to create a molecular patient database for Sjogren's syndrome and systemic lupus erythematosus. The collaboration aims to enhance disease understanding through a unique longitudinal PanOmics database by analyzing biospecimens from hundreds of patients. Evotec will commercially exploit the data, while MHH will use it for academic research. This partnership could facilitate the development of personalized therapies for autoimmune diseases, addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
partnership
-
Rhea-AI Summary

Evotec SE launched its PanOmics data analysis platform, PanHunter, at Bio-IT World on October 18, 2022. This software-as-a-service (SaaS) product aims to empower scientists by providing comprehensive access to vast PanOmics data sets, accelerating R&D processes and improving drug discovery success rates. With a significant increase in publicly available PanOmics data, PanHunter is designed to stratify patient populations and predict drug efficacy and toxicity, marking a notable advancement in data-driven medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
none
Rhea-AI Summary

Evotec and Toronto Innovation Acceleration Partners (TIAP) have expanded their LAB150 partnership to include Amgen as a strategic partner, committing a combined investment of US$ 14 million. This collaboration aims to enhance the development of Canada's life science companies by streamlining the transition from academic research to market-ready products. LAB150 has evaluated over 150 projects and currently supports 10 projects. Amgen will provide financial backing and mentorship to these initiatives, accelerating commercialization efforts and fostering innovation in the sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
partnership

FAQ

What is the current stock price of Evotec (EVO)?

The current stock price of Evotec (EVO) is $4.21 as of March 3, 2025.

What is the market cap of Evotec (EVO)?

The market cap of Evotec (EVO) is approximately 1.5B.

What does Evotec AG specialize in?

Evotec AG specializes in drug discovery, development, and biologics manufacturing through innovative technologies and collaborative partnerships.

How does Evotec generate revenue?

Evotec generates revenue through fee-for-service contracts, co-owned R&D partnerships, and biologics CDMO services under its Just-Evotec Biologics segment.

What is J.POD® technology?

J.POD® is Evotec’s proprietary continuous manufacturing platform for biologics, offering scalable, cost-effective, and flexible production solutions.

Who are Evotec’s key partners?

Evotec collaborates with all Top 20 pharmaceutical companies, over 800 biotech firms, academic institutions, and healthcare stakeholders worldwide.

What therapeutic areas does Evotec focus on?

Evotec focuses on neurology, oncology, metabolic diseases, and infectious diseases, addressing significant unmet medical needs.

What differentiates Evotec from its competitors?

Evotec stands out through its co-owned R&D pipeline, AI-driven drug discovery platforms, and innovative biologics manufacturing capabilities.

Where are Evotec’s operations located?

Evotec operates globally, with key sites in Europe and the United States, functioning as synergistic clusters of excellence.

What is Evotec's approach to sustainability?

Evotec integrates sustainability into its operations, with initiatives like J.POD® facilities designed to reduce water, electricity, and chemical usage.

What is the role of AI/ML in Evotec's operations?

AI/ML technologies enhance Evotec’s drug discovery processes by accelerating early-stage research and reducing development costs.

What is the significance of Evotec’s co-owned R&D model?

The co-owned R&D model allows Evotec to share risks and rewards with partners, fostering innovation and creating a robust pipeline of therapeutic candidates.
Evotec Ag

Nasdaq:EVO

EVO Rankings

EVO Stock Data

1.53B
354.61M
2.7%
0.22%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg